These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24556260)

  • 1. Paliperidone-associated motor tics.
    Hsieh MH; Chiu NY
    Gen Hosp Psychiatry; 2014; 36(3):360.e7-8. PubMed ID: 24556260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
    Mantas C; Kalabokis G; Goulia P; Tourlakopoulos A; Hyphantis T; Mavreas V
    J Clin Psychopharmacol; 2010 Feb; 30(1):89-91. PubMed ID: 20075663
    [No Abstract]   [Full Text] [Related]  

  • 3. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
    Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
    Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
    Jones A
    J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
    Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
    Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral-paliperidone-induced tardive dyskinesia: a case report.
    Wei HT; Lai YW; Chen MH; Chen YS
    Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone for schizophrenia.
    Dolder C; Nelson M; Deyo Z
    Am J Health Syst Pharm; 2008 Mar; 65(5):403-13. PubMed ID: 18281731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
    Han C; Lee SJ; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):650-1. PubMed ID: 21163319
    [No Abstract]   [Full Text] [Related]  

  • 15. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.
    Rodríguez-Martínez A; Quilo CG
    Clin Drug Investig; 2013 Dec; 33(12):867-76. PubMed ID: 24241935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
    Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone for treatment of schizophrenia.
    Nussbaum AM; Stroup TS
    Schizophr Bull; 2008 May; 34(3):419-22. PubMed ID: 18375569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
    Cleton A; Rossenu S; Crauwels H; Berwaerts J; Hough D; Gopal S; Eerdekens M; Vandebosch A; Remmerie B; De Meulder M; Rosso CM
    J Clin Pharmacol; 2014 Sep; 54(9):1048-57. PubMed ID: 24676998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.
    Na KS; Kim WH; Jung HY; Ryu SG; Min KJ; Park KC; Kim YS; Yoon JS; Ahn YM; Kim CE
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):295-300. PubMed ID: 22796278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.